Mycovia Pharmaceuticals presented data from its Phase 3, randomized, double-blind, placebo-controlled VIOLET studies, which measured the efficacy and safety of oteseconazole (VT-1161) in treating recurrent…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.